Early trial aims to supercharge immune system against cancer
NCT ID NCT02668770
Summary
This is an early-stage study to find the safest dose of a new drug, MGN1703, when given with an existing immunotherapy drug, ipilimumab. It involves about 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to see how much of the new drug can be given safely and to look for early signs that the combination might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.